Main points:
Review of sector Market:
This week (1.24 ~ 1.28), Shenwan beauty care sector – 5.52%. Shanghai Composite Index and gem index were – 4.57% and – 4.14% respectively. Shenwan beauty care sector lost 0.95pct to Shanghai Composite Index and 1.38pct to gem index.
Wind medical beauty and cosmetics index: this week, the CSI 300 index was – 4.51%, and the wind medical beauty index was – 7.12%, underperforming the CSI 300 market by 2.61 PCT; The wind cosmetics index was – 6.28%, underperforming the CSI 300 market by 1.77pct.
Industry highlights:
The Foresight Research Institute released the panorama of China’s cosmetics industry in 2022, pointing out that China’s cosmetics supervision is gradually standardized and domestic brands are rising. It is estimated that the scale of China’s cosmetics market will exceed 150 billion US dollars in 2027, and the male skin care and fragrance market will be increasingly sought after by consumers. (prospective economist)
Company announcement:
Sihuan pharmaceutical: the new drug marketing applications of insulin aspart injection, insulin aspart 30 injection and insulin aspart 50 injection developed by Huisheng biology, a non wholly-owned subsidiary of Sihuan pharmaceutical, have been accepted by the State Food and drug administration.
Shanghai Haohai Biological Technology Co.Ltd(688366) : the annual performance forecast for 2021 is released, and the net profit attributable to the parent company is expected to be 350 million yuan ~ 380 million yuan, with a year-on-year increase of 52% ~ 65%; It is estimated that the net profit deducted from non parent company is 320 million yuan to 350 million yuan, with a year-on-year increase of 57% ~ 71%.
Ruili Yimei: issued a profit warning. It is expected to achieve a revenue of about 190 million yuan in 2021 and a loss of about 18 million yuan attributable to the shareholders of the parent company.
Investment advice
(1) cosmetics industry: in January, Amoy’s online skin care Gmv was 8.8 billion yuan (yoy-32%), of which, Proya Cosmetics Co.Ltd(603605) (+ 14%) bucked the trend, becoming the only domestic brand in Amoy’s top 10 and ranking first among domestic skin care brands. Focus on: [ Yunnan Botanee Bio-Technology Group Co.Ltd(300957) ] subdivide the leaders in the field of sensitive muscle skin care; [ Proya Cosmetics Co.Ltd(603605) ] diversified high-quality brands; [ Shanghai Jahwa United Co.Ltd(600315) ] multi category development and continuous innovation to create new items; [ Guangdong Marubi Biotechnology Co.Ltd(603983) ] mainly focuses on medium and high-end, with rich marketing and distribution channels; [ Syoung Group Co.Ltd(300740) ] strong operation capacity and gradual improvement of category structure;
(2) medical beauty industry: the demand side of the medical beauty industry continues to expand, the supply side products are more diversified, and the policy side strengthens the supervision of medical beauty institutions and medical beauty products. We are optimistic about upstream medical and American enterprises with class III medical device certificate and perfect product matrix layout and downstream medical institutions with long-term standardized operation. Attention: [ Bloomage Biotechnology Corporation Limited(688363) ] local hyaluronic acid raw material leader; [ Imeik Technology Development Co.Ltd(300896) ] Tongyan needle is heavily listed and differentiated to meet higher demand; [ Huadong Medicine Co.Ltd(000963) ] overall layout of medical and American business; [ Shanghai Haohai Biological Technology Co.Ltd(688366) ] integration of R & D, production and sales; [tetracyclic medicine] botulinum toxin + double antibody go hand in hand; Pay attention to Lancy Co.Ltd(002612) and so on.
Risk tips
The risk of intensified industry competition; Uncertainty of industrial regulatory policies; Macroeconomic fluctuations, etc.
